Clinical Trial Update: Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure [Phase 1, Phase 2]

View source ↗

Summary

A randomized, double-blind, placebo-controlled study evaluating ITI-214 for safety and tolerability in patients with systolic heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• ITI-214

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Heart Failure, Systolic | Phase 1, Phase 2 | Status: COMPLETED